OncLive SOSS

Authors

Seungtaek L. Choi, MD

Latest:

Dr. Choi on Considering Factors for RT in Prostate Cancer

Seungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical Medical Director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the considering factors for patients to receive radiation therapy (RT) for their prostate cancer.

Shagun Arora, MD

Latest:

Building Upon Scaffolds

Cancer care is changing rapidly, and understanding and incorporating new practices is challenging both for practicing oncologists and oncology trainees.

Shailaja Raj MD

Latest:

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Shaji K. Kumar, MD

Latest:

Dr. Kumar on Updated Data from the MAIA Trial in Newly Diagnosed Multiple Myeloma

Shaji Kumar, MD, discusses the updated data from the phase 3 MAIA trial in newly diagnosed multiple myeloma.

Shaji K. Kumar, MD, Mayo Clinic College of Medicine

Shaji Kumar, MD

Latest:

Dr Kumar on Key Treatment Considerations for Myeloma Following NCCN Guideline Updates

Shaji Kumar, MD, discusses notable therapy considerations for multiple myeloma following the 2024/early 2025 NCCN guidelines update.

Shaji Kumar, MD, Mayo

Shaji Kumar, MD, Mayo Clinic

Latest:

There's No Place Like a Medical Home: Premier Medical Group Focuses on Full-scale Patient-Centered Care

It's not uncommon for a business to use a superlative in its name, but Premier Medical Group in Poughkeepsie, NY, truly lives up to its moniker.

Shalom Kalnicki, MD

Latest:

Novel Radiation Oncology Research Makes Population Health Strategies Smarter

For the past 5 years, Montefiore has been a leading Pioneer Accountable Care Organization (ACO) in CMS’ ACO program, which aims to improve the quality of care for Medicare beneficiaries while identifying ways to save healthcare dollars.

Sham Mailankody, MBBS

Latest:

Dr. Mailankody on BCMA CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Sham Mailankody, MBBS, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.

Shana Wingo, MD

Latest:

Dr. Wingo on the Evolution of Surgery in Endometrial Cancer

Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses the evolution of surgery in endometrial cancer.

Shane A. Meehan, MD

Latest:

Dr. Meehan on Importance of IHC Testing in Melanoma

Shane A. Meehan, MD, associate professor, Ronald O. Perelman Department of Dermatology, associate professor, Department of Pathology, director of the Dermatopathology Fellowship Training Program, and director of the Dermatopathology Section at New York University Langone Medical Center, discusses the importance of immunohistochemistry (IHC) testing in melanoma.

Shanel B. Bhagwandin, DO, MPH

Latest:

Surgery in Oncology Is Not Always a Simple Decision

The personalization of cancer care is more elaborately expressed in multidisciplinary tumor conferences and clinical trials.

Shannon Connelly

Latest:

Novel Frontline Regimen Improves PFS in Older Patients With MCL

The 4-drug combination of rituximab, bendamustine, bortezomib, and dexamethasone was found to improve progression-free survival and demonstrated a tolerable safety profile as frontline treatment for patients with mantle cell lymphoma who are ≥65 years.

Shannon N. Westin, MD

Latest:

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab ± Olaparib as a First-Line Treatment for Newly Diagnosed Advanced or Recurrent Endometrial Cancer: Results From the Phase III DUO-E/GOG-3041/ENGOT-EN10 Trial

Shannon Westin, MD, reviews the results of the Phase III DUO-E/GOG-3041/ENGOT-EN10 trial in patients with newly diagnosed advanced or recurrent endometrial cancer.

Shannon N. Westin, MD, MPH

Latest:

Patient-Centered Approaches to Frontline Low-Grade Ovarian Cancer: Optimizing Treatment, Quality of Life, and Fertility Preservation

Expert perspectives from Shannon Westin, MD, MPH, FACOG, on frontline treatment options for patients with newly diagnosed low-grade serous ovarian cancer in the context of recent clinical trial data. Dr. Westin discusses optimizing treatment strategies while prioritizing quality of life and fertility preservation for patients.

Shannon N. Westin, MD, MPH, FACOG

Latest:

FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

Dr Westin discusses the FDA approval of durvalumab plus chemotherapy for patients with dMMR advanced or recurrent endometrial cancer.

Shannon N. Westin, MD, MPH, The University of Texas MD Anderson Cancer Center

Latest:

Role of Combination I/O in Advanced Endometrial Cancer (EC)

Shannon N. Westin, MD, MPH, FACOG, discusses the rationale for the use of combination immunotherapy for advanced and recurrent endometrial cancer.